Biosimilars Market Report 2025 (Global Edition)

Global Biosimilars Market Report 2024 Market Size Split by Product Type (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-Inflammatory Agents, Pegfilgrastim, Others), by Distributio...

Biosimilars Market Report Description

We have various report editions of Biosimilars Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape

Many well-known and emerging firms, such as Novartis AG, Amgen Inc., Pfizer Inc., and Samsung Bioepis, have made their mark on the sector, making the global market extremely competitive in terms of the competitive environment. In the development of these complex pharmaceuticals at reasonable prices, these corporations have a major advantage over rising competitors because of their strong financial support, advanced technological know-how, and clinical trial experience. Additionally, these businesses are putting a lot of effort into getting regulatory approval for their medication in several different nations for a variety of uses. Other competitors in the developing market include Celltrion, Biocon, and Coherus BioSciences. These companies are expanding the reach of their products through strategic agreements that fortify their R&D capabilities and distribution network, to increase their market shares and product availability in significant nations.
 

Top Companies Market Share in Biosimilars Industry: (In no particular order of Rank)

• Novartis AG
• Pfizer Inc.
• Amgen
• Samsung Bioepis
• Shanghai Henlius Biotech
• Inc.
• Biocon
• Biogen
• Celltrion Inc.
• Cpherus BioSciences.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Biosimilars Market Regional Analysis

Region and country analysis section of Biosimilars Industry Analysis has been segmented into 5 major region such as North America, Europe, Asia Pacific, Middle East & Africa ,and Latin America (along with respective major contributing countries) and provides the revenue share, current trends.

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of Biosimilars market.

The current report Scope analyzes Biosimilars Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Biosimilars Market Analysis

By Product

Monoclonal antibodies, which hold the largest market share, are anticipated to rise at a compound annual growth rate (CAGR) of XX% during the estimated period. These are therapeutic classes that are becoming more and more popular in the treatment of chronic illnesses like cancer. The market participants' increasing emphasis on receiving regulatory clearances for many drug indications is fuelling the expansion of this business. For example, Samsung Bioepis Co., Ltd. and Sandoz inked a contract in September 2023 to commercialize SB17, a planned biosimilar to Janssen Pharmaceuticals' Stelara (Ustekinumab). A monoclonal antibody (mAb) called stemanib (Ustekinumab) is used to treat autoimmune diseases such as ulcerative colitis, psoriatic arthritis, Crohn's disease, and plaque psoriasis. (Source: https://www.sandoz.com/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing/)

Filgrastim and peg-filgrastim are the drugs growing at the fastest rate. Over the projected period, they are anticipated to grow at a CAGR of XX%. Patients with non-myeloid malignancies have a decreased risk of infection when using this treatment class. These products have longer half-lives and slower rates of elimination, so they don't need to be used every day. Because of this, therapy becomes more widely available over time, which raises the number of users of these medications and fuels the market's expansion.

• Monoclonal Antibodies
• Recombinant Hormones
• Immunomodulators
• Anti-Inflammatory Agents
• Pegfilgrastim 
• Others

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Biosimilars Industry. Request a Free Sample PDF!

By Distribution

Hospital pharmacies have the largest share and are expected to grow at a CAGR of XX5 during the forecast period. Due to healthcare professionals informing patients about the cost and efficacy of these products, the frequency of their purchase in hospital settings is increasing. Furthermore, several governments' reimbursement policies are encouraging its use in certain situations. Consequently, it is anticipated that each of these factors will boost the overall growth of the industry. 

Internet pharmacies are the fastest-growing segment, with a projected compound annual growth rate (CAGR) of XX% throughout the projection period. due to the benefits, it offers over other marketplaces, such as ensuring quick drug delivery to the client's door, which greatly promotes the segment's growth.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Biosimilars Disease Indication Segment Analysis

By Disease Indication 

Autoimmune conditions have the largest market share and are anticipated to develop at a compound annual growth rate (CAGR) of XX% over the projected period. Common illnesses like psoriasis and arthritis are covered in this section. The population with autoimmune illnesses is getting older, and as a result, there is a growing demand for easily accessible ways to follow treatment plans. The Centers for Disease Control and Prevention (CDC) reported in 2021 that 50% of those 65 years of age and older had an arthritis diagnosis. Consequently, to fulfill the increasing demand that is propelling the segment's expansion, the market participants are concentrating on obtaining regulatory approvals for these indications.

Oncology is the fastest-growing market and is expected to grow at a CAGR of XX% during the forecast period. According to NCBI, Cancer is a major cause of death and a major barrier to raising the average lifetime in every nation. According to estimates, there are expected to be approximately 10.0 million cancer-related fatalities (9.9 million excluding non-melanoma skin cancers) and 19.3 million new cases of cancer globally by 2020. With an expected 2.3 million new cases (11.7%), breast cancer (BC) has surpassed lung cancer (11.4%) as the most common malignancy diagnosed in women. The next most common cancers are stomach (5.6%), prostate (7.3%), and colon (10.0%). With 1.8 million predicted deaths (18%), lung cancer continued to be the most common cause of cancer-related mortality. The following five cancer-related causes of death were: colorectal (9.4%), gastric (7.7%), hepatic (8.3%), and women's breast (6.9%) cancers. Clinical trials are underway for several pipeline candidates for various cancers, which is one of the main factors expected to accelerate the segment's growth during the projected period. Renal and retinal illnesses are the other disorders treated in this section. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784530/) 
 

• Blood Disorders
• Growth Hormonal Deficiency
• Autoimmune Disorders
• Oncology
• Other

Biosimilars Type of Manufacturing Segment Analysis

• In-House Manufacturing
• Contract Manufacturing

Biosimilars Procedure Segment Analysis

• Invasive
• Non-Invasive

Biosimilars Disease Segment Analysis

• Stroke
• Dementia
• Epilepsy

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion